In Westlaw Today, life sciences regulatory & compliance partners Greg Levine and Joshua Oyster and counsel Sarah Blankstein discuss how it remains to be seen whether the changes FDA proposes in the draft guidance will in practice provide meaningful flexibility or lead to additional scrutiny over manufacturer communications regarding truthful, non-misleading information about unapproved uses for approved or cleared products.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.